Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain

Amber Tong

Paul Schloesser

Associate Editor

Apellis Pharmaceuticals still can’t pinpoint exactly what’s behind the rare cases of eye inflammation that’s been reported in patients taking its geographic atrophy drug Syfovre …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain

Amber Tong

Paul Schloesser

Associate Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

FDA approves Ionis’ treatment for a rare metabolic disorder

Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Associate Editor

Sign up to read this article for free.

more like this

Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain